कृपया अन्य खोज का प्रयास करें
Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics in Australia. The company’s lead drug candidate is the pezadeftide, which has completed phase II clinical trials for the treatment of onychomycosis. Hexima Limited was incorporated in 1997 and is headquartered in Bundoora, Australia.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Justin Yap | - | 2018 | Non-Executive Director |
Mark G. Lebwohl | - | - | Member of Scientific Advisory Board |
Phoebe Rich | - | 2021 | Member of the Scientific Advisory Board |
Tracey C. Vlahovic | - | 2021 | Member of the Scientific Advisory Board |
Peter Foley | - | 2021 | Member of the Scientific Advisory Board |
Shari Lipner | - | 2021 | Member of the Scientific Advisory Board |
Warren S. Joseph | - | 2021 | Member of the Scientific Advisory Board |
Geoffrey Paul Kempler | 68 | 2023 | MD & Chairman |
Boni Elizabeth Elewski | - | 2021 | Member of the Scientific Advisory Board |
Shinichi Watanabe | - | 2021 | Member of the Scientific Advisory Board |
Robert Rosen | - | 2021 | Member of the Scientific Advisory Board |
Richard K. Scher | - | 2021 | Member of the Scientific Advisory Board |
Christopher Mews | - | 2023 | Director |
Phillip Hains | - | 2023 | Non-Executive Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है